Abstracts tagged "thyroid"

Abstract Number: 1471 • 2019 ACR/ARP Annual Meeting
Polyautoimmunity and Major Organ Involvement Prevalence in Sjögren´s Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study
Larissa Valor¹, Hannah Schenker ², Johannes Knitza ³, Melanie Hagen ³, Jürgen Rech ⁴ and Georg Schett ⁵, ¹Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Polyautoimmunity has been described to be associated with primary Sjögren´s syndrome (SjS) and the most frequent observed associated autoimmune diseases (AID) are autoimmune thyroid…
Abstract Number: 2072 • 2019 ACR/ARP Annual Meeting
Prevalence of Thyroid Dysfunction with Therapeutic Indication in Patients with Rheumatological Diseases
Sho Fukui ¹, Genki Kidoguchi¹, Takehiro Nakai ², Satoshi Kawaai ¹, Hiroki Ozawa ¹, Ayako Koido ¹, Yukihiko Ikeda ¹, Masei Suda ¹, Haruyuki Yanaoka ¹, Hisanori Shimizu ¹, Hiromichi Tamaki ¹, Tokutaro Tsuda ¹, Mitsumasa Kishimoto ³, Kenichi Yamaguchi ¹ and Masato Okada ¹, ¹St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ²St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Thyroid dysfunction (TD) is known as a common complication of rheumatological diseases (RD). Treatment for TD is important not only in clinical TD for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].